Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines-Reference-Cited by-同舟云学术

Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines

Published:2021-12-22 Issue:3 Volume:9 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Montoya José G.¹^ORCID,Adams Amy E.²,Bonetti Valérie¹,Deng Sien³,Link Nan A.²,Pertsch Suzanne²,Olson Kjerstie¹,Li Martina³,Dillon Ellis C.³,Frosch Dominick L.³

Affiliation:

1. Dr. Jack S. Remington Laboratory for Specialty Diagnostics, Palo Alto Medical Foundation Research Institute, Palo Alto, California, USA

2. Palo Alto Foundation Medical Group, Palo Alto, California, USA

3. Center for Health Systems Research, Sutter Health, Palo Alto Medical Foundation Research Institute, Palo Alto, California, USA

Abstract

SARS-CoV-2 vaccines using the mRNA platform have become one of the most powerful tools to overcome the COVID-19 pandemic. mRNA vaccines enable human cells to produce and present the virus spike protein to their immune system, leading to protection from severe illness. Two mRNA vaccines have been widely implemented, mRNA-1273 (Moderna) and BNT162b2 (Pfizer/BioNTech).

Funder

Sutter Health | Palo Alto Medical Foundation

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/Spectrum.01162-21

Reference18 articles.

1. The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020

2. Audio Interview: Advice for Clinicians on Covid-19 Vaccines and Social Restrictions

3. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine